Ultragenyx Cash Flow Conversion Efficiency
Ultragenyx cash flow conversion efficiency. Based on the latest financial reports, Ultragenyx (RARE) has a cash flow conversion efficiency ratio of 0.342x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-97.00 Million) by net assets ($-284.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Ultragenyx (2011–2025)
Cash flow conversion efficiency of Ultragenyx from 2011 to 2025. This chart illustrates how Ultragenyx's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Ultragenyx for real-time trading data and today's change.
Ultragenyx Cash Flow Conversion Ratio Explained
Ultragenyx cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Ultragenyx Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ultragenyx ranked by their cash flow conversion efficiency. Also see RARE stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eastern Communications Co Ltd A
SHG:600776
|
-0.006x |
|
Vestjysk Bank A/S
CO:VJBA
|
0.003x |
|
Baoding Lucky Innovative Materials Co Ltd
SHE:300446
|
0.007x |
|
Daqo New Energy Corp ADR
NYSE:DQ
|
-0.025x |
|
Concord Biotech Limited
NSE:CONCORDBIO
|
N/A |
|
Absci Corp
NASDAQ:ABSI
|
-0.112x |
|
Shanghai DaZhong Public Utilities Group Co Ltd
SHG:600635
|
0.022x |
|
DL E&C Co Ltd
KO:375500
|
0.027x |
Annual Cash Flow Conversion Efficiency for Ultragenyx (2011–2025)
The table below shows the annual cash flow conversion efficiency of Ultragenyx from 2011 to 2025. Review RARE free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-73.00 Million | $-466.00 Million | 6.384x | +504.26% |
| 2024-12-31 | $262.30 Million | $-414.19 Million | -1.579x | +8.40% |
| 2023-12-31 | $275.41 Million | $-474.81 Million | -1.724x | -59.72% |
| 2022-12-31 | $352.49 Million | $-380.46 Million | -1.079x | -194.00% |
| 2021-12-31 | $922.56 Million | $-338.69 Million | -0.367x | -220.53% |
| 2020-12-31 | $1.15 Billion | $-132.22 Million | -0.115x | +78.32% |
| 2019-12-31 | $653.76 Million | $-345.38 Million | -0.528x | -10.71% |
| 2018-12-31 | $608.91 Million | $-290.57 Million | -0.477x | +27.92% |
| 2017-12-31 | $383.45 Million | $-253.84 Million | -0.662x | -94.92% |
| 2016-12-31 | $473.97 Million | $-160.97 Million | -0.340x | -70.20% |
| 2015-12-31 | $531.09 Million | $-105.98 Million | -0.200x | +17.32% |
| 2014-12-31 | $184.94 Million | $-44.63 Million | -0.241x | +61.24% |
| 2013-12-31 | $50.11 Million | $-31.20 Million | -0.623x | -319.98% |
| 2012-12-31 | $84.34 Million | $-12.50 Million | -0.148x | +72.91% |
| 2011-12-31 | $10.64 Million | $-5.83 Million | -0.547x | -- |
About Ultragenyx
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth fac… Read more